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Abstract
Objective To assess the cost effectiveness of the Find and Treat service
for diagnosing and managing hard to reach individuals with active
tuberculosis.
Design Economic evaluation using a discrete, multiple age cohort,
compartmental model of treated and untreated cases of active
tuberculosis.
Setting London, United Kingdom.
PopulationHard to reach individuals with active pulmonary tuberculosis
screened or managed by the Find and Treat service (48mobile screening
unit cases, 188 cases referred for case management support, and 180
cases referred for loss to follow-up), and 252 passively presenting
controls from London’s enhanced tuberculosis surveillance system.
Main outcomemeasures Incremental costs, quality adjusted life years
(QALYs), and cost effectiveness ratios for the Find and Treat service.
Results The model estimated that, on average, the Find and Treat
service identifies 16 and manages 123 active cases of tuberculosis each
year in hard to reach groups in London. The service has a net cost of
£1.4 million/year and, under conservative assumptions, gains 220
QALYs. The incremental cost effectiveness ratio was £6400-£10
000/QALY gained (about €7300-€11 000 or $10 000-$16 000 in
September 2011). The two Find and Treat components were also cost
effective, even in unfavourable scenarios (mobile screening unit (for
undiagnosed cases), £18 000-£26 000/QALY gained; casemanagement
support team, £4100-£6800/QALY gained).
Conclusions Both the screening and case management components
of the Find and Treat service are likely to be cost effective in London.
The cost effectiveness of the mobile screening unit in particular could
be even greater than estimated, in view of the secondary effects of
infection transmission and development of antibiotic resistance.
Introduction
The incidence of tuberculosis in the UK has increased
consistently over the past two decades.1 2 More than 9000 cases
are reported every year, with 38% of cases occurring in London.2
This increase has been associated with a change in the
epidemiology of the disease: although tuberculosis affected the
general population in the past, most cases now occur in high
risk groups. In particular, tuberculosis is widely recognised to
be associated with social risk factors, including homelessness,
problematic drug use, and imprisonment.3 Previous work
suggests that the outcome of care in these population groups is
probably suboptimal.3 4 In a recent study, the estimated
prevalence of tuberculosis in hard to reach groups in London
was 788 per 100 000 in homeless people, 354 per 100 000 in
people with problematic drug use, and 208 per 100 000 in
prisoners. By comparison, the overall prevalence of tuberculosis
in London was 27 per 100 000 people.3 Although only 17% of
tuberculosis cases in London are in hard to reach people, they
account for nearly 38% of non-treatment adherent cases, 44%
of cases lost to follow-up, and 30% of all highly infectious
cases.3 Tuberculosis control therefore needs targeted
interventions to address transmission in these groups.
In April 2005, the English Department of Health provided
funding to set up a mobile radiography unit to actively screen
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for tuberculosis disease in London’s vulnerable populations, in
view of their low rate of presentation for passive care. The
service visits locations where high risk groups can be found,
including drug treatment services and hostels or day centres for
homeless and impoverished people. All individuals are screened
on a voluntary basis regardless of symptom status.
Since September 2007, the mobile screening unit has been
encompassed by the “Find and Treat” service. This service aims
not only to screen and find active cases, but also to raise
awareness, undertake case holding, and provide support for
treatment completion for the same hard to reach groups. The
unit has visited 210 locations across most London primary care
trusts, with a median of 52 individuals screened at each location
per year. The service uses links with drug and alcohol support
services, hostels, and street outreach and criminal justice services
to find cases and to maintain contact with patients during
treatment to ensure completion. The availability of staff
members to accompany patients to appointments and for home
visits reduces the risk of cases being lost to follow-up.
Awareness raising events take place in venues across London
such as hostels, which are particularly supported by peer
workers—individuals from high risk groupswho have completed
treatment for tuberculosis. The service not only oversees cases
referred by the mobile screening unit, but also those referred
by tuberculosis clinics across London, who are non-adherent to
treatment or lost to follow-up care before treatment completion.
Mobile screening services have also been successfully trialled
in the Netherlands and Zimbabwe,5 6where they seem to have
potentially rapid effects on tuberculosis transmission and
disease.5 The UK secretary of state for health has recently
suggested that initiatives like the Find and Treat service could
be implemented in cities such as Birmingham, where the
prevalence of tuberculosis is rising.7
We aimed to evaluate the cost effectiveness of the Find and
Treat service from September 2007 to July 2010 in London,
using a decision analytical model set up with patient level data.
As the service reaches the end of its pilot phase, the economic
assessment of these interventions will help to inform key policy
decisions on tuberculosis control in London and elsewhere.
Methods
Decision problem
We evaluated the cost effectiveness of the Find and Treat service
by considering costs and outcomes of three groups: patients
identified by the mobile screening unit with active pulmonary
tuberculosis on chest radiograph examination and further
diagnostic tests, patients referred to the service for enhanced
case management support (that is, to ensure they complete
treatment successfully), and patients referred to the service
because they had been lost to follow-up. As controls in our
study, we used the current method of passive case finding
combined with ad hoc outreach in some primary care trusts,
because no other interventions targeting hard to reach cases of
tuberculosis have been trialled in London. We compared the
following options: having no Find and Treat service, having
only one part of the service (the mobile screening unit or the
case management component), and having both parts of the
service. We undertook the evaluation from the perspective of
the healthcare taxpayer perspective.
Data sources
We used the Find and Treat database to obtain information on
individuals with active pulmonary tuberculosis screened or
managed by the service with record dates between September
2007 and September 2010. Records were not available before
September 2007. Although the service used to screen a large
number of prisoners, it has mostly stopped since the introduction
of radiograph machines in prisons for active case finding in new
inmates.
Cases detected by the mobile screening unit and engaged with
the Find and Treat service were compared with passively
detected control cases with active pulmonary tuberculosis (that
is, individuals who presented to London tuberculosis services
of their own accord without screening and referral to the Find
and Treat service). We excluded patients with non-pulmonary
tuberculosis since they would not be detected by chest
radiography. A passively presenting group was the most
appropriate control, because they received the care services that
would be available in London in the absence of Find and Treat.
We selected controls from passively detected cases in London
that were notified to the Health Protection Agency’s enhanced
tuberculosis surveillance system2 between 1 January 2009 (when
the system began recording risk factor information) and 9
August 2010. We chose controls that were age matched with
actively detected cases (within five year age categories) and
that displayed one or more risk factors (a history of
homelessness or imprisonment, drug or alcohol abuse, or mental
health problems).
We obtained risk factor and clinical information for Find and
Treat cases and passively presenting controls from the enhanced
tuberculosis surveillance system. Case information was
supplemented with data from the Find and Treat database. For
each Find and Treat patient, we obtained the date of first screen
(for those referred by the mobile screening unit), treatment
outcome, and date of outcome, by matching patients to records
in the enhanced tuberculosis surveillance system. For patients
with symptoms on screening, we calculated diagnostic delays
as the time from reported symptom onset to the start of
treatment. We obtained dates of symptom onset and treatment
by approaching individual clinics when they were not recorded
in the databases. If the date of symptom onset was not available,
we used the date when the patient sought clinical help. We
calculated times to the final outcome as the difference between
the date when the service engaged the patient and the date of
treatment or episode completion.
The study included 75 mobile screening unit cases, 231 cases
referred for case management support, 263 cases referred
following loss to follow-up, and 315 passively presented control
cases.We excluded cases of extrapulmonary tuberculosis, latent
tuberculosis, and suspected tuberculosis; cases merely receiving
prophylaxis (and hence unlikely to have active tuberculosis);
cases for which the diagnostic delay could not be calculated;
and cases younger than 16 years. After these exclusions, the
study had 48 mobile screening unit cases, 188 cases referred
for case management support, 180 cases referred for loss to
follow-up, and 252 passively presenting control cases.
Compartmental model structure
We used a discrete, multiple age cohort, compartmental model8
to model a population of individuals with active tuberculosis.
Individuals in the model can occupy one of four health states:
active untreated tuberculosis, active treated tuberculosis with
up to 125 days of continuous treatment, active treated
tuberculosis with more than 125 days of continuous treatment,
and lost to follow-up. We split patients undergoing treatment
by duration of treatment (with a 125 day cut off), which provided
a better fit to data (web appendix). In our model, patients moved
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between these health states as they started treatment, completed
treatment, were lost to follow-up, and re-engaged with treatment
(fig⇓).
Every year, cases also have a probability of entering four final
outcomes (from which they do not leave): completion of
treatment, death due to tuberculosis related causes, death due
to other causes, and other final outcomes that the Find and Treat
service is not expected to change (such as patients being
transferred out of London or stopping treatment for clinical
reasons). To estimate the rate of death from causes not related
to tuberculosis, we used 2009 all cause mortality rates from the
Office for National Statistics. The model followed patients for
the remainder of their lives.
The model included actual cases of active pulmonary
tuberculosis that had been recorded as screened or managed by
the Find and Treat service between September 2007 and
September 2010. Since the recruitment period covered three
years, we estimated that, on average, the service identified 16
andmanaged 123 individuals with active tuberculosis each year.
Patients entered the model at the age when they were recorded
as being detected by the mobile screening unit or referred to the
service for case management.
For each case category (that is, cases screened, referred because
of complex management issues, or referred after loss to
follow-up), we compared the outcomes of a model cohort
managed by the Find and Treat service with the outcomes of an
equivalent cohort not managed by the service (based on
passively detected controls). We then estimated the rates of
transition between health states (table 1⇓). We assumed that
Find and Treat cases without confirmed active tuberculosis had
no additional health benefit or detriment as a result of
encountering the service.
Costs and quality of life weights
Untreated cases of active tuberculosis were assumed to have a
utility score of 0.68 (standard error 0.5), based on the mean
EQ-5D score given to cases diagnosed with tuberculosis in
London9 (individual level data obtained from M Kruijshaar,
personal communication). The EQ-5D is a standardised
instrument used to measure quality of life and its use is preferred
by the National Institute for Health and Clinical Excellence
(NICE). This utility score of 0.68 was also reported in a
Canadian study using an alternative instrument to measure
quality of life, the SF-6D.10 For the patients in London, EQ-5D
scores improved to 0.81 (standard error 0.04) after 2 months of
treatment. Hence we assumed that in the first year of treatment,
patients would have an intermediate utility score of 0.79, before
reaching a score of 0.81 in subsequent years.9We assumed cases
without active tuberculosis to have the same utility score as
population norms.11Table 2⇓ summarises the economic variables
used in the model.
We obtained costs for staff salaries, training and development,
travel and subsistence, administration, maintenance, cleaning,
insurance, fuel, office management, and radiography equipment
maintenance in 2009-10 from the Find and Treat records. We
increased staff costs to take into account qualification and capital
overhead costs, by mapping job descriptions of Find and Treat
staff to their nearest equivalents (in terms of role and salary)
from standard costing sources.12We did not include non-capital
overhead costs, since these were already part of the Find and
Treat annual budget.
Chest radiography costs were already included in the overall
Find and Treat budget. Patients referred for diagnostic testing
(regardless of whether they were subsequently found to have
active tuberculosis) were assumed to incur the cost of a
laboratory culture test, estimated from the tariff cost for
microbiological pathology services.13 We estimated the cost of
treating a case of tuberculosis from NICE guidelines.14 Also,
increased treatment costs were associated with multidrug
resistant patients.14Based on Find and Treat data, 0.5% ofmobile
screening unit patients and 5.3% of other Find and Treat patients
had multidrug or extensively drug resistant infection (table 1);
the remaining patients’ infections were not resistant or were
resistant to only one drug. We inflated costs to 2009-10 prices
using the hospital and community health services pay and prices
index.12
We then added up the costs incurred and quality adjusted life
years (QALYs) associated with each health state (fig), with and
without the Find and Treat service, with future costs and benefits
discounted at a rate of 3.5% per year as recommended by
NICE.15
To determine the cost effectiveness of the two components of
the Find and Treat service, we allocated costs between the
mobile screening unit and the case management team according
to the estimates given in the Find and Treat budget (including
qualification and capital overhead costs). However, we
transferred an additional amount from the case management
service budget to the mobile screening unit budget to represent
enhanced follow-up of screened cases, based on the proportion
of cases followed up who were identified by the mobile
screening unit.
Sensitivity analysis
To test the robustness of the results, we made several
assumptions (individually and in combination) that were less
favourable to Find and Treat.
Increased costs for mobile screening unit
Instead of using standard UK National Health Service capital
overheads for the cost of the unit, we assumed that a newmobile
unit would need to be purchased, and that it would last five
years before being decommissioned. We assumed the cost of a
new unit to be £600 000 (excluding maintenance costs, which
were already incorporated in the unit’s running budget). We
added this amount to the costs of the first year of the service,
with discounted costs and outcomes totalled over five years.
Increased cost of tuberculosis treatment
Instead of using costs for tuberculosis treatment from a NICE
report, we used higher figures from a costing study,16 and
inflated them to 2009-10 prices using the pay and prices index
for hospital and community health services. This gave costs of
£8300 and £75 000 for treatment of drug sensitive andmultidrug
resistant tuberculosis, respectively.12
Improved quality of life for untreated tuberculosis
case, and poor quality of life for tuberculosis
cases on treatment
We raised the QALY weight for untreated tuberculosis cases
to the upper 95% limit of the sampling distribution of its mean
(utility score 0.76). We also lowered the QALY weight for
treated tuberculosis cases to 0.76 (so that putting patients on
treatment is not assumed to provide a better health related quality
of life until treatment is completed).
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Asymptomatic cases detected by mobile
screening unit do not always progress to
symptomatic disease
We assumed that only 50% of asymptomatic cases with a
positive result from the mobile screening unit would progress
to symptomatic disease.
Cases referred to Find and Treat service for
enhanced case management have a reduced
loss to follow-up rate in the absence of the
service
We assumed that Find and Treat cases would be lost to
follow-up at the same rate as enhanced tuberculosis surveillance
controls (17.2% per year) in the absence of the service, rather
than at the higher rate we estimated for this extremely hard to
reach group (34.7% per year).
Cases referred to Find and Treat service for loss
to follow-up could still passively re-engage with
treatment
We assumed that even without Find and Treat involvement,
these cases could still passively re-engage with treatment at the
same rate as enhanced tuberculosis surveillance controls (51%
per year).
Results
Transition rates of cases managed and not
managed by Find and Treat
The web appendix provides estimated values and full details of
the estimation procedure used to compare the transition rates
between health states in the two cohorts.
Previously untreated cases referred for treatment
after detection by mobile screening unit
We estimated that the 22.9% of patients detected by the mobile
screening unit with the longest delays between symptom onset
and treatment presentation were unlikely to present for treatment
without the activities of the Find and Treat service. Furthermore,
35.4% of mobile screening unit patients were asymptomatic on
detection, and hence would not have presented for treatment
without the unit. We assumed that asymptomatic patients would
progress rapidly to symptomatic disease,17 and that in the
absence of the Find and Treat service, they would behave
similarly to symptomatic patients (that is, some would present
for treatment, but 22.9%would not). Once on treatment, mobile
screening unit cases managed by the Find and Treat service had
a much lower risk of loss to follow-up than passively presenting
controls (loss to follow-up probability after one year: 2.1% for
cases, 17.2% for controls).
Cases referred to Find and Treat service for case
management support
We found that cases referred to Find and Treat because of
complex casemanagement issues had higher rates of completing
treatment (61.2% after one year) and lower rates of loss to
follow-up (3.3% after one year) than controls.
Cases under treatment referred to Find and Treat
service because of loss to follow-up
We estimated that 51.7% of cases of active pulmonary
tuberculosis referred to the Find and Treat service because of
loss to follow-up would subsequently return to the service. We
estimated cases become lost to follow-up after re-engagement
at an annual rate of 34.7%. Once this happens, we estimated
that the annual probability of re-engagement if cases were again
lost to follow-up was 81.7%; we assumed the remaining cases
to be permanently lost. Since these lost cases have little hope
of re-engaging with treatment after referral, we assumed that,
in the absence of the Find and Treat service, these cases would
not be re-engaged.
Cost effectiveness of Find and Treat service
Table 3⇓ shows the costs incurred and QALYs accrued by the
cohort of active tuberculosis cases described in this report, for
scenarios with and without the Find and Treat service. We
estimated that every year the service has a net cost of £1.4
million and gains 220 QALYs. Hence the incremental cost
effectiveness of the Find and Treat service was estimated to be
£6400/QALY gained. The web appendix shows how the service
affects the health state of cases over time.
We also found both components of the service to be cost
effective at the same threshold. The mobile screening unit had
an incremental ratio of £18 000/QALY gained, whereas the case
management component had an incremental ratio of
£4100/QALY gained. The ratio increased slightly whenwe used
assumptions that were more unfavourable to the Find and Treat
service, but not enough to change the overall conclusion (table
4⇓). In the most unfavourable (and highly unlikely) scenario,
which combined all the unfavourable assumptions, the mobile
screening unit and case management components had
incremental ratios of £26 000/QALY gained and £6800/QALY
gained, respectively.
Discussion
Principal findings, strengths, and limitations
of study
The Find and Treat service appears to be cost effective, based
on a threshold of £20 000-£30 000/QALY gained, used by
NICE.15 Although analyses of each Find and Treat component
should be interpreted with caution because of overlapping costs
between the two services, they both seem to be cost effective
separately. We obtained similar results when we made
assumptions that were more unfavourable to the Find and Treat
service. In the most unfavourable case, in which data were
interpreted unfavourably in five instances to create a very highly
unlikely scenario, the mobile screening unit had an incremental
cost effectiveness ratio of about £26 000 (table 4). NICE would
often still consider this ratio to be acceptable,15 particularly since
during model parameterisation, whenever data were not
available, we made conservative assumptions to ensure that the
benefit of Find and Treat was not overestimated.
One limitation of our analysis is the absence of a trial
randomising tuberculosis cases to be either managed or not
managed by the Find and Treat service. The absence of
randomisation meant that we could not be sure of the outcomes
of Find and Treat managed cases if the service did not exist.
Consequently, we based ourmodel of such outcomes on controls
with active tuberculosis in London’s enhanced tuberculosis
surveillance systemwho presented for care. Although we chose
controls to have at least one risk factor to represent the potential
target population for the Find and Treat service, the service also
manages extremely hard to reach individuals, who are often
already lost to follow-up at the time of referral or who would
never present for care without the mobile screening unit. Hence
the comparison of cases with retrospective controls probably
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underestimates the incremental benefit of the service, although
we cannot be certain without a randomised study.
Furthermore, the methods used for the modelling do not fully
capture the benefits of the Find and Treat service. For example,
we did not incorporate secondary transmission into the economic
evaluation, even though the mobile screening unit in particular
probably averts several secondary cases by finding highly
infectious individuals. For example, in a study of a large ongoing
epidemic of isoniazid resistant tuberculosis in London in 2004,18
researchers found 87 cases with traceable contacts, who had
525 contacts between them. Of these contacts, 355 completed
screening and 11% of these screened contacts became cases.
Another simplification was that we did not measure the effect
of the Find and Treat service on reducing the likelihood of
patients developing and transmitting acquired drug resistance
(as a result of poor treatment adherence). Drug resistance
increases the duration and costs of treatment, as well as the risk
of severe disease, thus prevention could be an important benefit
of the service. Full capture of these benefits would need a
dynamic transmission model. However, since both Find and
Treat components already seem cost effective without
incorporating dynamic effects, the use of a static model appears
to be justified.
Comparisons with other studies and
implications
There is wide international consensus that the provision of
untargeted chest radiograph examination to the whole population
for tuberculosis detection is largely ineffective.17 19 There is also
agreement that prompt diagnosis and adequate treatment of
active cases is the most crucial element of tuberculosis control.
Evaluations of interventions to actively find cases, such as
radiological screening of high risk groups, suggest that not only
can the screening of high risk groups detect cases more
effectively than door to door symptom based screening,5 but
also that transmission can be interrupted when the intervention
is appropriately targeted.6 The accompanying editorial to the
trial by Corbett and colleagues, while supporting active case
finding in high prevalence groups, argued that any attempt to
scale up such interventions in the community should be
accompanied by systems that ensure treatment completion and
an assessment of cost effectiveness.20
London has seen a resurgence of tuberculosis on a scale not
seen in any other western European capital in the past two
decades.21-23 The incidence of tuberculosis in the London
borough of Brent is comparable to that in Karonga District in
Malawi.2 24 It is therefore appropriate that any intervention that
provides a cost effective means to identify cases promptly and
ensure that they complete treatment is an essential component
of the tuberculosis control programme. This study shows that
the Find and Treat service provides an intervention that detects
hard to reach cases of symptomatic and asymptomatic
tuberculosis, and ensures that they receive treatment. The cost
effectiveness compares favourably with other interventions
currently funded to control tuberculosis in the UK.14 For
example, the dual strategy of tuberculin skin testing and
interferon gamma release assay testing has an incremental cost
effectiveness ratio of £29 955/QALY gained, and universal
BCG vaccination of school children has a ratio of £56
000/QALY gained (assuming 0.05% infection prevalence and
10 years of vaccine protection).
The true value of the Find and Treat service to public health
will only fully be realised when a cost effective rapid point of
care diagnostic tool becomes available. Although there are
promising reports of rapidmolecular tests endorsed by theWorld
Health Organization,25 26 there is currently no test to accurately
detect true latent infection, and molecular assays would benefit
from further field evaluation in this setting.
In conclusion, this study shows that the London Find and Treat
service is a cost effective intervention. Indeed, both the
screening and case management support components of the
intervention are likely to be cost effective in London. Although
the Find and Treat service alone will probably not reverse the
rise in tuberculosis in London, it will probably be helpful to the
individuals who have the greatest evidence of ongoing
transmission.27 Further studies should assess using point of care
testing within community outreach settings such as the mobile
screening unit, as well as the role of community based delivery
of treatment. Additionally, a randomised trial comparing patients
managed and not managed by the Find and Treat service would
enable estimates of the service’s benefits to bemade with greater
certainty.
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Tables
Table 1| Yearly transition rates (%) in model for cases detected or managed by Find and Treat service and for passively treated control
cases
Control casesFind and Treat cases
Previously untreated cases referred for treatment after screening by Find and Treat service
46.254.6Completed treatment (if in first year of treatment)
56.867.1Completed treatment (if in subsequent year of treatment)
17.22.1Lost to follow-up
00Died from tuberculosis related causes
8.510.1
Had final outcome other than treatment completion, tuberculosis related death, or
loss to follow-up
51.051.0Re-engaged with treatment after loss to follow-up
Cases referred to Find and Treat service for case management support because of complex issues
51.761.2Completed treatment
3.33.3Died from tuberculosis related causes
34.72.6Lost to follow-up
9.611.3Had final outcome other than treatment completion, tuberculosis related death, or
loss to follow-up
51.051.0Re-engaged with treatment after loss to follow-up
Cases under treatment referred to Find and Treat service because of loss to follow-up
081.7Re-engaged with treatment (of the 51% who do eventually re-engage)
34.734.7Lost again to follow-up (if on treatment)
40.841.0Completed treatment (if on treatment)
2.62.2Died from tuberculosis related causes
7.67.6Had final outcome other than treatment completion, tuberculosis related death, or
loss to follow-up
Untreated cases*
22.922.9Died from tuberculosis related causes
21.021.0Recovered
Categories specific to Find and Treat cases
–35.4Cases with asymptomatic active tuberculosis (as % of mobile screening unit cases)
–22.9Extremely hard to reach cases (diagnostic delay >131 days) (as % of mobile
screening unit cases)†
–51.7Cases that are found and re-engage with treatment (as % of active tuberculosis
cases referred to Find and Treat service for loss to follow-up)
Multidrug resistant or extensively drug resistant active tuberculosis cases‡
–0.5Mobile screening unit cases
–5.3Other Find and Treat cases
Rates estimated by matching Find and Treat records to enhanced tuberculosis surveillance data, unless stated otherwise.
*Rates estimated by analysis of cases from south Indian study.28
†Includes cases that would not be diagnosed without mobile screening unit.
‡Rates estimated by analysis of Find and Treat records.
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Table 2| Economic variables in model
SourceCost/utility score
Find and Treat service
Find and Treat budget*£530 024Mobile screening unit
Find and Treat budget†£512 825Case management team
Treatment (per case)
NICE report16£5522Non-multidrug resistant tuberculosis
NICE report16£31 329Multidrug resistant tuberculosis
National Health Service reference costs15£7.12Tuberculosis sputum test
Quality of life weights
EQ-5D study110.68Active tuberculosis, untreated
EQ-5D study110.79Active tuberculosis, first year of treatment
EQ-5D study110.81Active tuberculosis, second and subsequent year of treatment
*Breakdown of costs: staff costs for registrar, nurse, administrator, driver, and radiographer (£345 624); training and development (£20 000); travel and subsistence
(£4800); contracted administration (£15 000); maintenance and cleaning (£25 000); insurance and fuel (£18 000); radiography maintenance (£50 000); and office
and management (£51 600).
†Breakdown of costs: staff costs for nurse, social worker, outreach worker, clinical lead and contracted nurse (£361 225); training and development (£30 000);
travel and subsistence (£3200); contracted administration (£15 000); and office and management (£103 400).
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Table 3| Costs incurred and QALYs accrued by active tuberculosis cases with and without Find and Treat service
DifferenceWithout Find and TreatWith Find and Treat
Costs incurred
£1 000 000£0£1 000 000Find and Treat service
£400£330£730Diagnostic tests
£400 000£310 000£690 000Treatment
£1 400 000£310 000£1 700 000Total
QALYs accrued
48791Mobile screening unit for hard to reach patients
192948Mobile screening unit for extremely hard to reach patients
136578Mobile screening unit for asymptomatic cases
60520580Referrals because of complex case management issues
130220350Referrals because of loss to follow-up
2209201100Total
£6400––Incremental cost effectiveness ratio
Data are rounded to 2 significant figures.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2011;343:d5376 doi: 10.1136/bmj.d5376 (Published 13 September 2011) Page 9 of 11
RESEARCH
Table 4| Cost effectiveness comparison of Find and Treat components under unfavourable scenarios
Incremental cost effectiveness ratio
Scenario
Case managementMobile screening unitFind and Treat service (components
combined)
£4100£18 000£6400Base case
£4100£20 000£6700Increased mobile screening unit costs
£5600£18 000£7600Increased treatment costs
£4200£19 000£6500Improved quality of life for untreated tuberculosis and poor quality of life
for treated tuberculosis
£4100£22 000£6500Asymptomatic mobile screening unit cases do not always progress to
symptomatic disease
£4600£18 000£7100Cases referred to Find and Treat service for enhanced case management
have lower rate of loss to follow-up than those not referred
£4700£18 000£7500Cases referred to Find and Treat service for loss to follow-up could
passively re-engage with treatment
£6800£26 000£10 000Most unfavourable scenario to Find and Treat service*
Data rounded to 2 significant figures. *All scenarios combined, apart from base case.
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Figure
Health states in compartmental model for active tuberculosis cases, managed by the Find and Treat service
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